Pharma

Integrins Gain Traction in Ophthalmology

With Integrins, Necessity Really is the Mother of all Invention

By Michelle Dalton | September 14, 2017

Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US…

Read More
Double Shot Gives Spark Therapeutics a Jolt

Double Shot Gives Spark Therapeutics a Jolt

By Rich Kirkner | July 26, 2017

Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…

Read More
Inotek May Be for Sale, But Who Will Buy?

Inotek May Be for Sale, But Who Will Buy?

By Steve Lenier | July 19, 2017

With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…

Read More
AGTC Makes Moves with Cash in Hand

AGTC Makes Moves with Cash in Hand

By Rich Kirkner | July 11, 2017

As Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…

Read More
Is AMD Drug-Treatment Landscape Shifting?

Is AMD Drug-Treatment Landscape Shifting?

By Rich Kirkner | June 28, 2017

When Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…

Read More
Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

By Rich Kirkner | May 31, 2017

With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…

Read More
Dry Eye Newbie Xiidra Grabs Large Market Share

Dry Eye Newbie Xiidra Grabs Large Market Share

By Michelle Dalton | May 19, 2017

During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat –…

Read More
With Positive Phase I/IIa, Opthea Looks to Next Step

With Positive Phase I/IIa, Opthea Looks to Next Step

By Rich Kirkner | April 20, 2017

Coming off word that the Phase I/IIa clinical trial of its novel anti-VEGF candidate for treatment of age-related macular degeneration exceeded expectations, along with positive…

Read More
Gottlieb Brings VC Toolkit to FDA

Gottlieb Brings VC Toolkit to FDA

By Rich Kirkner | April 12, 2017

Soon-to-be FDA commissioner, Scott Gottlieb, MD, is well positioned to understand where the medtech and biotech communities are coming from. He’s been a partner at…

Read More
AXIM Rolls Medical Marijuana Ball in Ophthalmology

AXIM Rolls Medical Marijuana Ball in Ophthalmology

By Rich Kirkner | April 5, 2017

Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative…

Read More
How Regeneron Aims to Stay on Message with VR/AR App

How Regeneron Aims to Stay on Message With VR/AR APP

By Steve Lenier | March 29, 2017

Virtual reality has been used to train surgeons, to evaluate balance control and associated fall risk in glaucoma patients, and, more recently, to create simulations…

Read More
Clearside Goes All In for CLS-TA

Clearside Goes All in for CLS-TA

By Rich Kirkner | March 15, 2017

Late last year, when developers of agents that combined anti-platelet derived growth factor with an anti-vascular endothelial growth factor (anti-PDGF/anti-VEGF) to treat wet age-related macular…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.